ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Iterum Therapeutics Announces NDA for Oral Sulopenem americanpharmaceuticalreview
January 29, 2021Iterum Therapeutics announced the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) in ... -
Iterum hit by failure of anti-infective sulopenem pharmatimes
June 04, 2020Shares in Dublin, Ireland and Chicago, US-based Iterum Therapeutics have taken a hit on news that the firm's sulopenem did not achieve statistical non-inferiority relative to ertapenem in a trial in complicated urinary tract infection (cUTI).
Pharma Sources Insight January 2025
